116 related articles for article (PubMed ID: 29071096)
1. A 6-month telephone-based weight loss intervention in overweight and obese subjects with idiopathic intracranial hypertension.
Weil R; Kovacs B; Miller N; McDermott MP; Wall M; Kupersmith M; Pi-Sunyer FX;
Obes Sci Pract; 2016 Jun; 2(2):95-103. PubMed ID: 29071096
[TBL] [Abstract][Full Text] [Related]
2. Effect of acetazolamide on visual function in patients with idiopathic intracranial hypertension and mild visual loss: the idiopathic intracranial hypertension treatment trial.
; Wall M; McDermott MP; Kieburtz KD; Corbett JJ; Feldon SE; Friedman DI; Katz DM; Keltner JL; Schron EB; Kupersmith MJ
JAMA; 2014 Apr 23-30; 311(16):1641-51. PubMed ID: 24756514
[TBL] [Abstract][Full Text] [Related]
3. The idiopathic intracranial hypertension treatment trial: clinical profile at baseline.
Wall M; Kupersmith MJ; Kieburtz KD; Corbett JJ; Feldon SE; Friedman DI; Katz DM; Keltner JL; Schron EB; McDermott MP;
JAMA Neurol; 2014 Jun; 71(6):693-701. PubMed ID: 24756302
[TBL] [Abstract][Full Text] [Related]
4. Headache in Idiopathic Intracranial Hypertension: Findings From the Idiopathic Intracranial Hypertension Treatment Trial.
Friedman DI; Quiros PA; Subramanian PS; Mejico LJ; Gao S; McDermott M; Wall M;
Headache; 2017 Sep; 57(8):1195-1205. PubMed ID: 28752894
[TBL] [Abstract][Full Text] [Related]
5. The Idiopathic Intracranial Hypertension Treatment Trial: A Review of the Outcomes.
Smith SV; Friedman DI
Headache; 2017 Sep; 57(8):1303-1310. PubMed ID: 28758206
[TBL] [Abstract][Full Text] [Related]
6. The idiopathic intracranial hypertension treatment trial: design considerations and methods.
Friedman DI; McDermott MP; Kieburtz K; Kupersmith M; Stoutenburg A; Keltner JL; Feldon SE; Schron E; Corbett JJ; Wall M;
J Neuroophthalmol; 2014 Jun; 34(2):107-17. PubMed ID: 24739993
[TBL] [Abstract][Full Text] [Related]
7. Use of sibutramine in obese mexican adolescents: a 6-month, randomized, double-blind, placebo-controlled, parallel-group trial.
García-Morales LM; Berber A; Macias-Lara CC; Lucio-Ortiz C; Del-Rio-Navarro BE; Dorantes-Alvárez LM
Clin Ther; 2006 May; 28(5):770-82. PubMed ID: 16861099
[TBL] [Abstract][Full Text] [Related]
8. Optic disc haemorrhages at baseline as a risk factor for poor outcome in the Idiopathic Intracranial Hypertension Treatment Trial.
Wall M; Thurtell MJ;
Br J Ophthalmol; 2017 Sep; 101(9):1256-1260. PubMed ID: 28130349
[TBL] [Abstract][Full Text] [Related]
9. Role of vitamin A metabolism in IIH: Results from the idiopathic intracranial hypertension treatment trial.
Libien J; Kupersmith MJ; Blaner W; McDermott MP; Gao S; Liu Y; Corbett J; Wall M;
J Neurol Sci; 2017 Jan; 372():78-84. PubMed ID: 28017254
[TBL] [Abstract][Full Text] [Related]
10. Weight reduction for a better visual outcome in idiopathic intracranial hypertension.
Koc F; Isik MR; Sefi-Yurdakul N
Arq Bras Oftalmol; 2018; 81(1):18-23. PubMed ID: 29538589
[TBL] [Abstract][Full Text] [Related]
11. Factors Affecting Visual Field Outcomes in the Idiopathic Intracranial Hypertension Treatment Trial.
Cello KE; Keltner JL; Johnson CA; Wall M;
J Neuroophthalmol; 2016 Mar; 36(1):6-12. PubMed ID: 26618282
[TBL] [Abstract][Full Text] [Related]
12. Idiopathic intracranial hypertension.
Ko MW
Curr Treat Options Neurol; 2011 Feb; 13(1):101-8. PubMed ID: 21063921
[TBL] [Abstract][Full Text] [Related]
13. CSF pressure, papilledema grade, and response to acetazolamide in the Idiopathic Intracranial Hypertension Treatment Trial.
Kattah JC; Pula JH; Mejico LJ; McDermott MP; Kupersmith MJ; Wall M
J Neurol; 2015 Oct; 262(10):2271-4. PubMed ID: 26159101
[TBL] [Abstract][Full Text] [Related]
14. Obesity and Weight Loss in Idiopathic Intracranial Hypertension: A Narrative Review.
Subramaniam S; Fletcher WA
J Neuroophthalmol; 2017 Jun; 37(2):197-205. PubMed ID: 27636748
[TBL] [Abstract][Full Text] [Related]
15. Safety and Tolerability of Acetazolamide in the Idiopathic Intracranial Hypertension Treatment Trial.
ten Hove MW; Friedman DI; Patel AD; Irrcher I; Wall M; McDermott MP;
J Neuroophthalmol; 2016 Mar; 36(1):13-9. PubMed ID: 26587993
[TBL] [Abstract][Full Text] [Related]
16. Visual Field Outcomes for the Idiopathic Intracranial Hypertension Treatment Trial (IIHTT).
Wall M; Johnson CA; Cello KE; Zamba KD; McDermott MP; Keltner JL;
Invest Ophthalmol Vis Sci; 2016 Mar; 57(3):805-12. PubMed ID: 26934136
[TBL] [Abstract][Full Text] [Related]
17. Risk factors for poor visual outcome in patients with idiopathic intracranial hypertension.
Wall M; Falardeau J; Fletcher WA; Granadier RJ; Lam BL; Longmuir RA; Patel AD; Bruce BB; He H; McDermott MP;
Neurology; 2015 Sep; 85(9):799-805. PubMed ID: 26245929
[TBL] [Abstract][Full Text] [Related]
18. A feasibility randomised controlled trial of a motivational interviewing-based intervention for weight loss maintenance in adults.
Simpson SA; McNamara R; Shaw C; Kelson M; Moriarty Y; Randell E; Cohen D; Alam MF; Copeland L; Duncan D; Espinasse A; Gillespie D; Hill A; Owen-Jones E; Tapper K; Townson J; Williams S; Hood K
Health Technol Assess; 2015 Jul; 19(50):v-vi, xix-xxv, 1-378. PubMed ID: 26168409
[TBL] [Abstract][Full Text] [Related]
19. Changes in weight, papilledema, headache, visual field, and life status in response to diet and metformin in women with idiopathic intracranial hypertension with and without concurrent polycystic ovary syndrome or hyperinsulinemia.
Glueck CJ; Golnik KC; Aregawi D; Goldenberg N; Sieve L; Wang P
Transl Res; 2006 Nov; 148(5):215-22. PubMed ID: 17145568
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
